These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17164812)

  • 1. Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation.
    Sarter M; Bruno JP; Parikh V
    Neuropsychopharmacology; 2007 Jul; 32(7):1452-61. PubMed ID: 17164812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic concepts of neurotransmission.
    Patel DR; Feucht C
    Pediatr Clin North Am; 2011 Feb; 58(1):21-31, ix. PubMed ID: 21281846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomic and molecular principles of psychopharmacology. A primer for psychiatrists.
    Heckers S; Konradi C
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):1-22. PubMed ID: 10674188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):68-77. PubMed ID: 22234284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical changes in the aging human brain: implications for behavioral impairment and neurodegenerative disease.
    Strong R
    Geriatrics; 1998 Sep; 53 Suppl 1():S9-12. PubMed ID: 9745628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats.
    Kozak R; Martinez V; Young D; Brown H; Bruno JP; Sarter M
    Neuropsychopharmacology; 2007 Oct; 32(10):2074-86. PubMed ID: 17299502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal vesicular trafficking and release in age-related cognitive impairment.
    Deák F
    J Gerontol A Biol Sci Med Sci; 2014 Nov; 69(11):1325-30. PubMed ID: 24809352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanisms and functions of spontaneous neurotransmitter release.
    Kavalali ET
    Nat Rev Neurosci; 2015 Jan; 16(1):5-16. PubMed ID: 25524119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders.
    Arnsten AF; Rubia K
    J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):356-67. PubMed ID: 22449642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G proteins: implications for psychiatry.
    Manji HK
    Am J Psychiatry; 1992 Jun; 149(6):746-60. PubMed ID: 1350427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders.
    Lau CG; Zukin RS
    Nat Rev Neurosci; 2007 Jun; 8(6):413-26. PubMed ID: 17514195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances.
    Chaudhry FA; Edwards RH; Fonnum F
    Annu Rev Pharmacol Toxicol; 2008; 48():277-301. PubMed ID: 17883368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
    Chang L; Cloak CC; Ernst T
    J Clin Psychiatry; 2003; 64 Suppl 3():7-14. PubMed ID: 12662128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of neurotransmitter systems by dehydroepiandrosterone and dehydroepiandrosterone sulfate: mechanism of action and relevance to psychiatric disorders.
    Pérez-Neri I; Montes S; Ojeda-López C; Ramírez-Bermúdez J; Ríos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1118-30. PubMed ID: 18280022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies.
    El Khoury MA; Gorgievski V; Moutsimilli L; Giros B; Tzavara ET
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):36-50. PubMed ID: 22300746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action.
    Jentsch JD; Roth RH; Taylor JR
    Prog Brain Res; 2000; 126():433-53. PubMed ID: 11105661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep brain stimulation, vagal nerve stimulation and transcranial stimulation: An overview of stimulation parameters and neurotransmitter release.
    Albert GC; Cook CM; Prato FS; Thomas AW
    Neurosci Biobehav Rev; 2009 Jul; 33(7):1042-60. PubMed ID: 19433105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of brain norepinephrine in the behavioral response to stress.
    Morilak DA; Barrera G; Echevarria DJ; Garcia AS; Hernandez A; Ma S; Petre CO
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Dec; 29(8):1214-24. PubMed ID: 16226365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neurotransmitters and behavioral disorders].
    Allain H; Schuck S
    Encephale; 1998 Jul; 24 Spec No 1():34-7. PubMed ID: 9809253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.